Woundsource Reports On The Role Of NovaBay Pharmaceuticals, Inc. (NBY)’s Neutrophase® In Treatment Of ‘Flesh-Eating’ Infections
4/17/2014 9:50:34 AM
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a clinical-stage biopharmaceutical company, today announced that WoundSource™ has highlighted NovaBay’s NeutroPhase wound cleanser in a recent blog posting. The blog explains why NeutroPhase can play an important role in treating life-threatening necrotizing fasciitis, or ‘flesh-eating’ infections.
Help employers find you! Check out all the jobs and post your resume.
comments powered by